Real-Time Signaling Assays Demonstrate Somatostatin Agonist Bias for Ion Channel Regulation in Somatotroph Tumor Cells

Journal of the Endocrine Society
Melissa RodriguezAgnes Schonbrunn

Abstract

Acromegaly is a neuroendocrine disorder caused by excess secretion of GH by somatotroph tumor cells. It is often treated with somatostatin receptor (SSTR) 2 agonists, which suppress GH secretion. SOM230 is a somatostatin analogue that targets multiple SSTRs and was recently approved for patients with treatment-resistant acromegaly. Previous reports indicate that SOM230 may function as a biased agonist, suggesting that its ability to selectively activate SSTR-dependent signaling events may contribute to its therapeutic efficacy. To better understand how SOM230 modulates Sstr2A function, which is the most commonly expressed SSTR in somatotrophs, we used real-time assays to study SOM230-dependent signaling in rat pituitary tumor cells. We observed that SOM230 suppressed cAMP production in a Gαi-dependent manner, similar to conventional Sstr2A agonists. However, it did not cause receptor internalization as would be expected for an Sstr2A agonist. Surprisingly, SOM230 did not cause membrane hyperpolarization, which is an important mechanism by which Sstr2a activation suppresses intracellular calcium (Ca2+) accumulation and GH secretion. In fact, SOM230 inhibited the ability of conventional somatostatin analogues to control membrane ...Continue Reading

References

Mar 21, 1996·Nature·S HerlitzeW A Catterall
Jun 19, 2001·Journal of Medicinal Chemistry·J E RivierJ C Reubi
Dec 6, 2003·Pharmacological Reviews·Annette C Dolphin
Feb 7, 2004·The Journal of Clinical Endocrinology and Metabolism·Joost van der HoekSteven W Lamberts
Apr 9, 2004·The Journal of Clinical Endocrinology and Metabolism·Leo J HoflandSteven W J Lamberts
Apr 28, 2005·Molecular Pharmacology·Qisheng LiuAgnes Schonbrunn
Nov 6, 2007·Molecular and Cellular Endocrinology·Herbert A Schmid
Jun 5, 2008·The Journal of Pharmacology and Experimental Therapeutics·Christopher MorreyRoberto Levi
Nov 13, 2008·The Journal of Clinical Endocrinology and Metabolism·Sarah LescheStefan Schulz
Apr 23, 2010·The Journal of Clinical Endocrinology and Metabolism·S PetersennUNKNOWN Pasireotide Acromegaly Study Group
Jul 24, 2010·Endocrine Reviews·Stanko S StojilkovicRichard Bertram
Dec 3, 2010·Endocrine Reviews·Annamaria ColaoRosario Pivonello
Aug 31, 2011·Journal of Visualized Experiments : JoVE·Jialie LuoHongzhen Hu
Sep 22, 2011·ACS Chemical Biology·Brock F BinkowskiKeith V Wood
Dec 6, 2011·Cell Calcium·Stanko S Stojilkovic
Nov 20, 2012·Sub-cellular Biochemistry·Christophe Altier
Feb 16, 2013·Nature Reviews. Drug Discovery·Terry Kenakin, Arthur Christopoulos
Jan 11, 2014·Trends in Endocrinology and Metabolism : TEM·Mounira ChalabiCorinne Bousquet
Sep 28, 2014·The Lancet. Diabetes & Endocrinology·Mônica R GadelhaUNKNOWN Pasireotide C2402 Study Group
Feb 15, 2015·Molecular Pharmacology·Edward L StahlLaura M Bohn
May 29, 2015·Drugs·Kate McKeage

❮ Previous
Next ❯

Methods Mentioned

BETA
transfection
biosensor
ELISA

Software Mentioned

Prism
GraphPad Prism

Related Concepts

Related Feeds

Calcium & Bioenergetics

Bioenergetic processes, including cellular respiration and photosynthesis, concern the transformation of energy by cells. Here is the latest research on the role of calcium in bioenergetics.